DNA methylating, chemotherapeutic agent. Displays antitumor activity against a board spectrum of tumors, including leukemias, lymphomas and solid tumors (IC50
= 5.0 μ
M for cytotoxicity against mouse TLX5 lymphoma cells). Induces autophagy in malignant glioma cells. Exhibits enhanced activity when used in combination with CHC
(Cat No. 5029).
Soluble to 50 mM in DMSO
Store at RT
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Plowman et al.
Cancer Res., 1994;54:3793
Antitumor imidazotetraazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide.
Clark et al.
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells.
Kanzawa et al.
Cell Death Differ., 2004;11:448
Formation of DNA adducts and induction of lacI mutations in big blue rat-2 cells treated with temozolomide: implications for the treatment of low-grade adult and pediatric tumors.
Bodell et al.
Cancer Epidemiol.Biomarkers Prevent., 2003;12:545
The citations listed below are publications that use Tocris products. Selected citations for Temozolomide include:
Showing Results 1 - 2 of 2